A carregar...
Complete response in a patient with lung cancer suffering from three pembrolizumab‐induced immune‐related adverse events including retinal vasculitis
A 71‐year‐old man was diagnosed with squamous cell lung carcinoma with high expression of programmed cell death ligand 1 (PDL1) (cT4N1M1b stage IVA). He was treated with pembrolizumab, but 14 days later, he suffered from pembrolizumab‐related retinal vasculitis as an immune‐related adverse event (ir...
Na minha lista:
| Publicado no: | Respirol Case Rep |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley & Sons, Ltd
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7938210/ https://ncbi.nlm.nih.gov/pubmed/33732464 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/rcr2.730 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|